1,133
Views
0
CrossRef citations to date
0
Altmetric
Editorial

How will tovorafenib change our treatment of pediatric low-grade glioma?

& ORCID Icon
Pages 1-3 | Received 13 Nov 2023, Accepted 29 Jan 2024, Published online: 02 Feb 2024
 

Declaration of interest

E Bouffet is a member of advisory board with Novartis and Alexion. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

Reviewer disclosures

Peer reviewers on this manuscript have no relevant financial or other relationships to disclose.

Additional information

Funding

This paper was not funded.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.